» Articles » PMID: 14723975

Therapeutic SiRNAs

Overview
Specialty Pharmacology
Date 2004 Jan 16
PMID 14723975
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

The ability of small-interfering RNAs (siRNAs) to silence gene expression in somatic mammalian cells has provided researchers with a novel tool to block the expression of disease-causing genes, provided that their mRNA sequences are known. siRNAs can be delivered to cells either exogenously as synthetic agents or endogenously as gene-encoding siRNAs. Recent studies demonstrate the general application of siRNAs to silence gene expression in a range of cell types and in whole mammals. Beyond their value for dissecting gene functions and target validation, siRNAs also hold great potential as gene-specific therapeutic agents.

Citing Articles

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy.

Moon Y, Jeon S, Shim M, Kim K Pharmaceutics. 2023; 15(2).

PMID: 36839734 PMC: 9965039. DOI: 10.3390/pharmaceutics15020411.


Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics.

Ewert K, Scodeller P, Simon-Gracia L, Steffes V, Wonder E, Teesalu T Pharmaceutics. 2021; 13(9).

PMID: 34575441 PMC: 8465808. DOI: 10.3390/pharmaceutics13091365.


Deep forest ensemble learning for classification of alignments of non-coding RNA sequences based on multi-view structure representations.

Li Y, Zhang Q, Liu Z, Wang C, Han S, Ma Q Brief Bioinform. 2020; 22(4).

PMID: 33367506 PMC: 8294561. DOI: 10.1093/bib/bbaa354.


Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.

Abdul Ghafoor Raja M, Katas H, Amjad M Asian J Pharm Sci. 2020; 14(5):497-510.

PMID: 32104477 PMC: 7032099. DOI: 10.1016/j.ajps.2018.12.005.


Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Swami R, Singh I, Khan W, Ramakrishna S Drug Deliv Transl Res. 2015; 3(6):593-610.

PMID: 25786377 DOI: 10.1007/s13346-013-0159-6.